Stay updated on INTRINSIC Clinical Trial: Tailored Metastatic CRC Therapies
Sign up to get notified when there's something new on the INTRINSIC Clinical Trial: Tailored Metastatic CRC Therapies page.

Latest updates to the INTRINSIC Clinical Trial: Tailored Metastatic CRC Therapies page
- Check3 days agoChange DetectedAdded Vall d'Hebron Institute of Oncology (VHIO) in Barcelona as a study site. The VHIO site is listed as Withdrawn.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; this appears to be a minor update without changes to study details or user-facing content.SummaryDifference0.0%

- Check25 days agoChange DetectedPage revision label updated from v3.2.0 to v3.3.1.SummaryDifference0.0%

- Check32 days agoChange DetectedFoundationOne®Liquid CDx diagnostic test has been added to identify genomic alterations for cohort assignment, and new arm details (including Inavolisib + Bevacizumab) with dosing information have been introduced. A new site location in Tainan, Taiwan (00704) and the KRAS G12C biomarker have been added to the study materials, with Hoffmann-La Roche listed as sponsor.SummaryDifference2%

- Check46 days agoChange DetectedMinor non-substantive updates are visible (such as updated last updated date and small adjustments to the locations list), while core study content—design, arms, primary/secondary outcomes, and eligibility criteria—remains unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedDates in the page's temporal list have been updated: newer dates added (2025-10-02, 2025-10-01, 2025-10) and older dates removed (2025-09-03, 2025-09-01, 2025-09).SummaryDifference0.3%

Stay in the know with updates to INTRINSIC Clinical Trial: Tailored Metastatic CRC Therapies
Enter your email address, and we'll notify you when there's something new on the INTRINSIC Clinical Trial: Tailored Metastatic CRC Therapies page.